Misplaced Pages

This is an old revision of this page, as edited by Whywhenwhohow (talk | contribs) at 23:01, 13 December 2024 (create). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Garadacimab is an experimental monoclonal antibody under investigation for the treatment of hereditary angioedema. Garadacimab is a humanized monoclonal antibody against the activated coagulation factor XIIa (FXIIa), with potential anti-inflammatory and anticoagulant activities.

Society and culture

Legal status

In December 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency (EMA) adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Andembry, intended for the prevention of recurrent attacks of hereditary angioedema. The applicant for this medicinal product is CSL Behring GmbH.

Garadacimab was designated an orphan medicine by the EMA.

Names

Garadacimab is the international nonproprietary name.

References

1. ^ "Andembry EPAR". European Medicines Agency (EMA). 12 December 2024. Retrieved 13 December 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
2. "Garadacimab (Code C166633)". NCI Thesaurus. 25 November 2024. Retrieved 13 December 2024. This article incorporates text from this source, which is in the public domain.
3. World Health Organization (2019). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 82". WHO Drug Information. 33 (3). hdl:10665/330879.

• Medicine

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.

• v
• t
• e

• Drugs not assigned an ATC code
• Orphan drugs
• Pharmacology stubs